Ajanta Pharma Ltd
NSE:AJANTPHARM
Ajanta Pharma Ltd
Revenue
Ajanta Pharma Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ajanta Pharma Ltd
NSE:AJANTPHARM
|
Revenue
₹45.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Revenue
₹312.3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Revenue
₹269.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Revenue
₹516B
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
7%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Revenue
₹113B
|
CAGR 3-Years
11%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Revenue
₹103.3B
|
CAGR 3-Years
18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Ajanta Pharma Ltd
Glance View
In the bustling landscape of the Indian pharmaceutical industry, Ajanta Pharma Ltd. has carved a niche for itself with a blend of strategic innovation and market smartness. Founded in 1973, the company swiftly harnessed the dynamics of a growing market by focusing on specialty therapeutic segments including cardiology, dermatology, ophthalmology, and pain management. With a distinctive approach that merges global aspirations with local market insights, Ajanta Pharma has established itself as a significant player not just in India, but also across over 30 countries. The company's success is driven by its sustained emphasis on research and development, which fuels its capabilities to roll out new, affordable formulations addressing unmet medical needs. Ajanta Pharma’s business model thrives on a two-pronged strategy: focusing on high-growth emerging markets and capitalizing on the constantly evolving healthcare demands in regulated markets like the United States. The company's adeptness at manufacturing efficiency and its vertically integrated operations enable it to maintain competitive cost structures, delivering value through robust margins. The revenue streams are further amplified by its prowess in developing generic drugs for the American market, where it navigates through complex regulatory landscapes to outpace competitors. Underpinned by a strong commitment to quality and patient-centric innovation, Ajanta Pharma’s operations exemplify a balanced growth trajectory, reinforcing its status as a dynamic and responsive healthcare entity.
See Also
What is Ajanta Pharma Ltd's Revenue?
Revenue
45.3B
INR
Based on the financial report for Dec 31, 2024, Ajanta Pharma Ltd's Revenue amounts to 45.3B INR.
What is Ajanta Pharma Ltd's Revenue growth rate?
Revenue CAGR 5Y
13%
Over the last year, the Revenue growth was 12%. The average annual Revenue growth rates for Ajanta Pharma Ltd have been 12% over the past three years , 13% over the past five years .
You don't have any saved screeners yet